These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 26575584

  • 1. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
    Xie C, Jin J, Bao X, Zhan WH, Han TY, Gan M, Zhang C, Wang J.
    Oncotarget; 2016 Jan 05; 7(1):610-21. PubMed ID: 26575584
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
    Hong SW, Park NS, Noh MH, Shim JA, Ahn BN, Kim YS, Kim D, Lee HK, Hur DY.
    Lung Cancer; 2017 Apr 05; 106():115-124. PubMed ID: 28285685
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 05; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 8. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M, Takahashi T, Yamamoto N, Koh Y.
    J Thorac Oncol; 2013 Mar 05; 8(3):259-69. PubMed ID: 23334091
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T.
    Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
    Kim DM, Kim MJ, Moon JH, Lee EY, Hong JK, Lee S, Koh DI, Ryu YS, Kim SM, Jung SA, Shin JS, Kim J, Park YS, Hong SW, Lee SH, Jung J, Park SS, Kim DY, Kim EH, Jeong HR, Gong JH, Kim J, Chan Kim S, Yu HN, Ki SY, Kim TW, Jin DH.
    Biochem Biophys Res Commun; 2020 Jun 18; 527(1):305-310. PubMed ID: 32446385
    [Abstract] [Full Text] [Related]

  • 14. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH, Seong MA, Lee HY.
    Oncotarget; 2016 Feb 16; 7(7):8184-99. PubMed ID: 26799187
    [Abstract] [Full Text] [Related]

  • 15. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, Chen YB.
    Oncotarget; 2015 Jun 10; 6(16):14329-43. PubMed ID: 25869210
    [Abstract] [Full Text] [Related]

  • 16. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
    Liao J, Lin J, Lin D, Zou C, Kurata J, Lin R, He Z, Su Y.
    Sci Rep; 2017 Apr 10; 7(1):781. PubMed ID: 28396596
    [Abstract] [Full Text] [Related]

  • 17. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.
    Cell Death Dis; 2015 Aug 06; 6(8):e1850. PubMed ID: 26247735
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z, Zhang SL, Hu X, Tam KY.
    Eur J Pharmacol; 2018 Nov 05; 838():41-52. PubMed ID: 30213498
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Botting GM, Rastogi I, Chhabra G, Nlend M, Puri N.
    PLoS One; 2015 Nov 05; 10(8):e0136155. PubMed ID: 26301867
    [Abstract] [Full Text] [Related]

  • 20. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
    Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne PA, Nakagawa K.
    Oncogene; 2016 Feb 18; 35(7):878-86. PubMed ID: 25961915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.